To refine our understanding of immune cell infiltration in stage III CRC patients across the ELNs-related subtypes, MIF was used to quantify CD3+, CD4 + and CD8 + T lymphocytes within tumor tissues (Fig. 5J). The gene discussed is CD8A; the disease is neoplasm.